Curation
PascalFrancis
Racine
Curation
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Parkinsonian syndrome after long-term treatment with clebopride

Identifieur interne : 002F65 ( PascalFrancis/Curation ); précédent : 002F64; suivant : 002F66

Parkinsonian syndrome after long-term treatment with clebopride

Auteurs : P. Montagna [Italie] ; A. S. Gabellini ; L. Monari ; E. Lugaresi

Source :

RBID : Pascal:92-0289118

Descripteurs français

English descriptors

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 7
A06       @2 1
A08 01  1  ENG  @1 Parkinsonian syndrome after long-term treatment with clebopride
A11 01  1    @1 MONTAGNA (P.)
A11 02  1    @1 GABELLINI (A. S.)
A11 03  1    @1 MONARI (L.)
A11 04  1    @1 LUGARESI (E.)
A14 01      @1 Inst. neurology @2 40123 Bologna @3 ITA
A20       @1 89-90
A21       @1 1992
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000023029590180
A44       @0 0000
A45       @0 9 ref.
A47 01  1    @0 92-0289118
A60       @1 P @3 CC
A61       @0 A
A64   1    @0 Movement disorders
A66 01      @0 USA
C02 01  X    @0 002B02U01
C03 01  X  FRE  @0 Toxicité
C03 01  X  ENG  @0 Toxicity
C03 01  X  GER  @0 Giftigkeit
C03 01  X  SPA  @0 Toxicidad
C03 02  X  FRE  @0 Homme
C03 02  X  ENG  @0 Human
C03 02  X  SPA  @0 Hombre
C03 03  X  FRE  @0 Etude cas
C03 03  X  ENG  @0 Case study
C03 03  X  SPA  @0 Estudio caso
C03 04  X  FRE  @0 Long terme
C03 04  X  ENG  @0 Long term
C03 04  X  SPA  @0 Largo plazo
C03 05  X  FRE  @0 Clébopride @2 NK @2 FR
C03 06  X  FRE  @0 Antiémétique
C03 06  X  ENG  @0 Antiemetic
C03 06  X  SPA  @0 Antiemético
C03 07  X  FRE  @0 Récepteur dopaminergique D2
C03 07  X  ENG  @0 D2 Dopamine receptor @6 «D2» Dopamine receptor
C03 07  X  SPA  @0 Receptor dopaminérgico D2
C03 08  X  FRE  @0 Antagoniste dopamine
C03 08  X  ENG  @0 Dopamine antagonist
C03 08  X  SPA  @0 Antagonista dopamina
C07 01  X  FRE  @0 Extrapyramidal syndrome
C07 01  X  ENG  @0 Extrapyramidal syndrome
C07 01  X  SPA  @0 Extrapiramidal síndrome
C07 02  X  FRE  @0 Système nerveux pathologie
C07 02  X  ENG  @0 Nervous system diseases
C07 02  X  SPA  @0 Sistema nervioso patología
N21       @1 198

Links toward previous steps (curation, corpus...)

Links to Exploration step

Pascal:92-0289118

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Parkinsonian syndrome after long-term treatment with clebopride</title>
<author>
<name sortKey="Montagna, P" sort="Montagna, P" uniqKey="Montagna P" first="P." last="Montagna">P. Montagna</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Inst. neurology</s1>
<s2>40123 Bologna</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Gabellini, A S" sort="Gabellini, A S" uniqKey="Gabellini A" first="A. S." last="Gabellini">A. S. Gabellini</name>
</author>
<author>
<name sortKey="Monari, L" sort="Monari, L" uniqKey="Monari L" first="L." last="Monari">L. Monari</name>
</author>
<author>
<name sortKey="Lugaresi, E" sort="Lugaresi, E" uniqKey="Lugaresi E" first="E." last="Lugaresi">E. Lugaresi</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">92-0289118</idno>
<date when="1992">1992</date>
<idno type="stanalyst">PASCAL 92-0289118 INIST</idno>
<idno type="RBID">Pascal:92-0289118</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003859</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002F65</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Parkinsonian syndrome after long-term treatment with clebopride</title>
<author>
<name sortKey="Montagna, P" sort="Montagna, P" uniqKey="Montagna P" first="P." last="Montagna">P. Montagna</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Inst. neurology</s1>
<s2>40123 Bologna</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Gabellini, A S" sort="Gabellini, A S" uniqKey="Gabellini A" first="A. S." last="Gabellini">A. S. Gabellini</name>
</author>
<author>
<name sortKey="Monari, L" sort="Monari, L" uniqKey="Monari L" first="L." last="Monari">L. Monari</name>
</author>
<author>
<name sortKey="Lugaresi, E" sort="Lugaresi, E" uniqKey="Lugaresi E" first="E." last="Lugaresi">E. Lugaresi</name>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1992">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiemetic</term>
<term>Case study</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine antagonist</term>
<term>Human</term>
<term>Long term</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Toxicité</term>
<term>Homme</term>
<term>Etude cas</term>
<term>Long terme</term>
<term>Clébopride</term>
<term>Antiémétique</term>
<term>Récepteur dopaminergique D2</term>
<term>Antagoniste dopamine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>7</s2>
</fA05>
<fA06>
<s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Parkinsonian syndrome after long-term treatment with clebopride</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>MONTAGNA (P.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>GABELLINI (A. S.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>MONARI (L.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>LUGARESI (E.)</s1>
</fA11>
<fA14 i1="01">
<s1>Inst. neurology</s1>
<s2>40123 Bologna</s2>
<s3>ITA</s3>
</fA14>
<fA20>
<s1>89-90</s1>
</fA20>
<fA21>
<s1>1992</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000023029590180</s5>
</fA43>
<fA44>
<s0>0000</s0>
</fA44>
<fA45>
<s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>92-0289118</s0>
</fA47>
<fA60>
<s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X">
<s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Toxicité</s0>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Toxicity</s0>
</fC03>
<fC03 i1="01" i2="X" l="GER">
<s0>Giftigkeit</s0>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Toxicidad</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Homme</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Human</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Hombre</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Etude cas</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Case study</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Estudio caso</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Long terme</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Long term</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Largo plazo</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Clébopride</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Antiémétique</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Antiemetic</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Antiemético</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Récepteur dopaminergique D2</s0>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>D2 Dopamine receptor</s0>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Receptor dopaminérgico D2</s0>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Antagoniste dopamine</s0>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Dopamine antagonist</s0>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Antagonista dopamina</s0>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
</fC07>
<fN21>
<s1>198</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F65 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002F65 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:92-0289118
   |texte=   Parkinsonian syndrome after long-term treatment with clebopride
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024